EUCTR2007-003898-42-DE进行中（未招募）不适用
Pharmacokinetica of levofloxacine in bone
Institut for Pharmacology and Toxicology0 个研究点目标入组 40 人开始时间: 2007年10月10日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •We will include patients (women and Men) from 40 to 65 years which are, für clinical reasons, undergoing a hip or knee replacement therapy in the participating entre. The patients must be able to understand and sign informed consent that the patients is willing to participate in the study.
- •Women must not be pregnant.
- •We will use only patients with no relevant and accompanying dieseases like:
- •prior traumatic surgery
- •past or present osteomyelitis
- •impaired function of the heart (>NYHA II)
- •impaired function of the kidney (creatinine > 1,5mg/dl)
- •impaired function of the liver (high GOT-value)
- •high body mass index (BMI > 35)
- •allergy against gyrase inhibitors
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients who are unable to consent will not be included in the study.
- •We will exclude patients with relevant and accompanying dieseases like:
- •prior traumatic surgery
- •past or present osteomyelitis
- •impaired function of the heart (>NYHA II)
- •impaired function of the kidney (creatinine > 1,5mg/dl)
- •impaired function of the liver (high GOT-value)
- •high body mass index (BMI > 35)
- •allergy against gyrase inhibitors
- •leucocytopenia
- •thrombocytopenia
研究者
相似试验
招募中
4 期
Pharmacokinetic study and safety of levofloxacin in pediatric tuberculosis treatmentMulti-drug resistant tuberculosisIsoniazid resistant tuberculosispatient with toxicity from the first line antituberculosisMDR-Hr-Toxicity from the first line anti-LevofloxacinTBTCTR20190515001Center of Excellence for Pediatric Infectious Diseases and Vaccines20
进行中（未招募）
1 期
Population pharmacokinetics of levofloxacin in intensive care patients with severe community-acquired pneumonia - Lévo-PharmMedDRA version: 14.0 Level: LLT Classification code 10032502 Term: Other specified alveolar and parietoalveolar pneumopathies System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorderscommunity-acquired pneumoniaEUCTR2011-002177-34-FRCHU de Toulouse65
已完成
3 期
Evaluation of the effect of oral levofloxacin on chronic endometritis in patientsIRCT20220413054524N1Shahre-kord University of Medical Sciences60
进行中（未招募）
1 期
Pharmacokinetic evaluation of moxifloxacin administered intravenously and orally in healthy volunteers who have had a gastric bypass.Healthy volunteers who have had a gastric bypass at least 6 months agoEUCTR2010-018628-14-BEniversity Ghent
进行中（未招募）
不适用
Pharmacokinetics and safety of moxifloxacin; a dose escalation in patients with tuberculosis - Pharmacokinetics and safety of moxifloxaciMedDRA version: 12.1Level: LLTClassification code 10044755Term: TuberculosisTuberculosisEUCTR2010-023491-25-NLniversity Medical Center Groningen